Literature DB >> 1434927

Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988.

A Riela1, A R Zinsmeister, L J Melton, L H Weiland, E P DiMagno.   

Abstract

To determine trends in the incidence of pancreatic cancer and associated survival, we conducted a population-based study in Olmsted County, Minnesota. From 1940 through 1988, 219 residents of Olmsted County (120 men and 99 women) were diagnosed as having exocrine pancreatic cancer. All patients were Caucasians, and 92% had a histologically confirmed diagnosis. The mean annual adjusted incidence of pancreatic cancer per 100,000 population was 8.5 overall (11.3 for men and 6.6 for women). During the course of the study, the incidence rates increased in women (P < 0.05) and in both genders combined (P = 0.06) but not in men (P = 0.4). The male:female ratio decreased from approximately 2:1 for 1940 through 1949 to 1.5:1 for 1980 through 1988. The incidence was significantly associated with increasing age (P < 0.001) and male gender (P < 0.001) but not calendar period (P = 0.19). The overall median duration of survival was 2.8 months. The 1-year survival rate was only 14%, and no patient lived for more than 55 months after pancreatic cancer was diagnosed. Men and women had similar survival rates. The increased incidence of pancreatic cancer among women may be due in part to the increasing life span of women and the increasing occurrence of pancreatic cancer in the aged.

Entities:  

Mesh:

Year:  1992        PMID: 1434927     DOI: 10.1016/s0025-6196(12)60821-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

Authors:  Peter Büchler; Howard A Reber; Mendel M Roth; Mark Shiroishi; Helmut Friess; Oscar J Hines
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  EUS Diagnostic Criteria for Chronic Pancreatitis: A Comparison of Conventional Versus Rosemont Criteria.

Authors:  Sharlene L D'Souza; Michelle A Anderson; Sheryl J Korsnes; B Joseph Elmunzer; Cyrus Piraka; Stacy Menees; Erik-Jan Wamsteker; Richard S Kwon; James M Scheiman; Grace H Elta
Journal:  Dig Dis Sci       Date:  2015-07-21       Impact factor: 3.199

3.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma.

Authors:  Robert R McWilliams; Gloria M Petersen; Kari G Rabe; Leonard M Holtegaard; Pamela J Lynch; Michele D Bishop; W Edward Highsmith
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

4.  Probability of pancreatic cancer following diabetes: a population-based study.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 5.  Adjuvant treatment strategies for pancreatic cancer.

Authors:  Erika A Newman; Diane M Simeone; Michael W Mulholland
Journal:  J Gastrointest Surg       Date:  2006-06       Impact factor: 3.452

Review 6.  Tropical chronic pancreatitis.

Authors:  K K Barman; G Premalatha; V Mohan
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

Review 7.  [Duodenum-preserving pancreas head resection-an operative technique for retaining the organ in the treatment of chronic pancreatitis].

Authors:  J Köninger; H Friess; M Müller; M Wirtz; M Martignioni; M W Büchler
Journal:  Chirurg       Date:  2004-08       Impact factor: 0.955

8.  To Study the Clinical, Biochemical and Radiological Features of Acute Pancreatitis in HIV and AIDS.

Authors:  Shahzad Raza; Naueen A Chaudhry; Jordan D Brown; Sina Aghaie; Damoun Rezai; Areej Khan; Paul De Leon Tan; Barbara J Berger
Journal:  J Clin Med Res       Date:  2013-01-11

9.  Rising incidence of pancreatic carcinoma in middle-aged and older women-time trends 1961-90 in the city of Malmö, Sweden.

Authors:  M Hedberg; H Anderson; A Borgström; L Janzon; S A Larsson
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.